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Abstract
I In nt tr ro od du uc ct ti io on n: :   Interactions between vascular endothelium and blood platelets
play a crucial role in cardiovascular diseases. Ex vitro models which use
endothelial cells and platelets were the essential tools to investigate these
interactions and their impact on haemostasis. The impaired interplay between
vascular endothelium, blood platelets and leukocytes is believed to contribute
to the development of cardiovascular disease. In this study we compared the
ability of human (HUVECs) and murine (HECa10) endothelial cells to inhibit
human platelet function and reactivity under in vitro conditions.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The aliquots of platelet-rich plasma obtained from 
20 healthy donors were incubated with murine endothelial cell line HECa10 or
human umbilical vein endothelial cells (HUVECs) (10 min, 37°C) prior to agonizing
platelets with 5 ﾵM ADP and monitoring platelet reactivity for 10 min using
optical aggregation.
R Re es su ul lt ts s: :   Significant reduction in ADP-induced platelet aggregation in the
presence of endothelial cell cultures remained independent of cell count. HUVECs
appeared much more effective in the inhibition of platelet aggregation compared
to HECa10 (35.2 ±2.3 AU vs. 43.7 ±2.0 AU, p = 0.025).
C Co on nc cl lu us si io on ns s: :    HECa10  cells  have  much  lower  potential  to  inhibit  platelet
aggregation than HUVECs. This implies that these two cell lines may not be
freely used interchangeably in in vitro experiments. These findings clearly indicate
that the outcomes of in vitro studies performed with murine EC lines cannot be
unreservedly extrapolated to human platelet-endothelium interactions.
K Ke ey y   w wo or rd ds s: :   endothelial cells, platelet aggregation.
Introduction
Vascular endothelium plays a major role in the inhibition of platelet
activation. This way it protects blood vessels against thrombosis [1].
The modulation of platelet reactivity using endothelial cells has been
proven to constitute a useful model for investigation of haemostatic
mechanisms [2] and in the research on antithrombotic agents [3].
Murine endothelial cell lines offer an interesting perspective for studying
C Co or rr re es sp po on nd di in ng g   a au ut th ho or r: :
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endothelial pathophysiology and pharmacology,
and  murine  models  of  endothelium-platelet
interactions have been occasionally employed
earlier [4]. However, there are no literature reports
on the modulation of human platelets by murine
endothelial lines. Due to some problems and
obstacles occurring with human endothelial cell
cultures  we  may  consider  the  application  of
murine endothelial cell lines as simple and not
expensive models for studying pharmacological
aspects of interactions of blood cells and vascular
endothelium.
The principal aim of this work was to compare
the  ability  of  HUVECs  (human  umbilical  vein
endothelial  cells)  and  murine  HECa10  (murine
endothelial  cell  line  [immortalized  hepatic
endothelial cells – clone HECa10]) to inhibit platelet
aggregation monitored under in vitro conditions
and  to  evaluate  how  far  these  two  cell  lines 
may be used exchangeably in the in vitro model
studies with a possible extrapolation to human
pathophysiology and pharmacology.
Material and methods
R Re ea ag ge en nt ts s   
The platelet agonist ADP was from Chrono-Log
(Havertown, PA USA). 
Unless stated otherwise, all other chemicals
were  from  Polish  Chemical  Reagents  (Gliwice,
Poland). 
B Bl lo oo od d   c co ol ll le ec ct ti io on n   
Blood was collected from 20 healthy donors 
(9 men and 11 women, mean age 27.5 ±11.5 years)
into  a vacuum  tube  (VacutainerTM,  Becton
Dickinson, San Diego, CA, USA) containing buffered
0.105 M sodium citrate (the final citrate : blood
ratio was 1 : 9 vol/vol). Blood was withdrawn with
special caution to avoid undesirable activation of
circulating platelets. Blood was centrifuged for 6 min
at 250 ￗ g to obtain platelet-rich plasma. In all
experiments platelet count in plasma was adjusted
to 2 ￗ 108 platelets/ml prior to use.
The study was performed under the guidelines
of the Helsinki Declaration for human research and
approved  by  the  committee  on  the  Ethics  of
Research in Human Experimentation at the Medical
University of Lodz (No. RNN/13/07/KB).
C Ce el ll l   c cu ul lt tu ur re es s   
The  murine  endothelial  cell  line  HECa10
(immortalized Hepatic Endothelial Cells – clone
HECa10),  a kind  gift  to  our  laboratory  from
Dr Claudine Kieda (Orl￩an, France), was used in
experiments. HEC were isolated from endothelium
of mouse peripheral lymph nodes immortalized by
transfection  which  involved  using  a plasmid
construct containing both the gene coding for the
large T antigen of simian virus 40 and a geneticin
resistance gene [5].
The continuous culture of cells was maintained
in culture flasks (Nunc EasY Flasks 25 cm2, NUNC).
Cells were cultured in RPMI 1640 medium (Sigma)
supplemented with 25 mM Hepes buffer (Sigma),
2  g/l  sodium  bicarbonate  (Sigma),  50  ﾵM 
2-mercaptoethanol (Sigma), 4 mM L-glutamine
(Sigma),  100  U/ml  penicillin  and  100  ﾵg/ml
streptomycin  solution  (Sigma),  0.1 mM  MEM
nonessential amino acid solution (Sigma), 1 mM
sodium pyruvate (Sigma), and 10% heat-inactivated
fetal calf serum (FCS, Biochrom) (complete RPMI),
and were kept at 37°C in a humidified atmosphere
of 95% air and 5% CO2. Twice a week, prior to
confluency,  cells  were  harvested  after  2-min
incubation at room temperature in the presence of
trypsin-EDTA  (0.05  and  0.02%  respectively)  in
Hanks-balanced salt solution (Sigma). Cells were
collected, washed three times in complete RPMI,
centrifuged and seeded at 1 ￗ 105 cells/ml of the
fresh medium [6].
Human  Umbilical  Vein  Endothelial  Cells
(HUVECs) and all reagents needed for cell culture
were purchased from Cascade Biologics (Portland,
Oregon, USA). HUVECs were cultured according to
the manufacturer’s instructions and cells underwent
2-10 passages. In platelet aggregation studies, both
HUVECs and HECa10 were suspended in Medium
200 at decreasing cell counts and, finally, the
amount of HUVECs in PRP was 9.9 ￗ 103 cells/ml or
6.6 ￗ 103 cells/ml or 3.3 ￗ 103 cells/ml [3].
M Me ea as su ur re em me en nt ts s   o of f   p pl la at te el le et t   r re ea ac ct ti iv vi it ty y
The platelet-rich plasma (PRP – 2 ￗ 108 pla  -
telets/ml)  was  incubated  (10  min,  37°C)  in
aggregation  cuvettes  with  HUVECs  or  HECa10
suspended in Medium 200 (3.3 ￗ 103 cells/ml)
without supplements. Medium 200 was used as
a controlling agent. In the first experiment we
investigated  the  ability  of  various  HUVEC
suspensions to inhibit platelet aggregation. In the
base experiment HUVECs were compared with
HECa10. The ability to inhibit platelet functions was
evaluated after incubation of (10 min, 37°C) HUVECs
or HECa10 with aliquots of PRP originating from the
same healthy donors.
Platelet reactivity, in the presence of 5 ﾵM ADP,
was monitored for 10 min using an optical ag  -
gregation method (Chrono-Log 490-2D, Havertown,
PA, USA) and aggregation curves were analysed
using the software “Platelet Aggregation Monitoring
and Analysis” (PAMA) [7]. The value of maximal
light transmission, Amax, reflecting the extent of
maximal platelet aggregation, was used for further
data analysis.
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S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Data are presented as mean ± SEM (standard
error of the mean). The Shapiro-Wilk test was used
to verify whether data were normally distributed
and Tukey multiple comparisons test was employed
to estimate the significance of differences between
groups.
Results
This  study  encompasses  two  lines  of
experiments. In the first line we observed a signi  -
ficant reduction in ADP-induced platelet aggregation
in the presence of HUVECs. Interes  tingly, this effect
was independent of the cell count in endothelial
cell cultures (Figure 1). 
In earlier work we applied a relatively high
concentration of ADP (10 ﾵM) and in the present
work we used 5 ﾵM ADP for platelet aggregation.
So we were afraid to overlook expected (subtle)
differences between tested endothelial cell lines.
In actual experimental conditions we observed
a much stronger inhibitive activity of endothelial
tissue. This took place once we used a lower
concentration of ADP (5 ﾵM ADP) than in the
previous experiment. It is worth noting that the
prior test required use of a higher concentration of
ADP (10 ﾵM ADP). 
In another series of experiments we also revealed
a significant antiplatelet effect on both HUVECs 
and HECa10. Both endothelial cell lines significan  -
tly  inhibited  ADP-induced  platelet  aggregation 
(Figure 2). To compare the ability of HUVECs and
HECa10 to inhibit platelet aggregation stimulated by
ADP we chose the suspension of 3.3 ￗ 103 cells/ml.
In our earlier studies we showed the inhibitory
effect of endothelial cells (EC) on blood platelets
depending on the EC count. The first effective
count which inhibits platelet aggregation was 
3.3 ￗ 103 cells/ml. We employed the examined
murine EC line at the same cell count in the present
study accordingly.
What is noteworthy, murine endothelial cells
inhibited human platelet aggregation to a consi  -
derably weaker extent than human endothelial cells
(Figure 2).
Discussion
The available literature shows a large variety of
different protocols and methodological approaches
employed for studying murine models to investigate
endothelial physiology [8, 9] and platelet-endo  -
thelium interactions [1, 3, 10-13]. Most researchers
applied HUVEC cells when conducting such studies
[3, 14-16], although the murine endothelial cell line
HECa10 was also occasionally used earlier [5, 6, 17].
However, it is the first study with the mixed model,
i.e. using a murine endothelial cell line and human
blood platelets for studying platelet-endothelium
interactions. In our present study we used low
concentrations of ADP as a platelet agonist that is
known to activate both platelets (activation and
aggregation) and endothelial cells via P2Y receptors
[18].  Our  data  are  consistent  with  what  we
demonstrated in our recent report, in which we
showed the inhibition of ADP-induced platelet
aggregation by HUVEC cells and revealed that the
effect was endothelial cell count dependent [3]. In
our present report we have not evidenced such
a distinct effect of cell count in the endothelial cell
cultures on platelet aggregation, which in our
opinion most likely results from the apparently low
concentration of ADP used in this experiment to
stimulate blood platelets. 
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F Fi ig gu ur re e   1 1. .   The effect of various endothelial cells
(HUVEC) count on ADP-induced (5 ﾵM) platelet
aggregation monitored under in vitro conditions.
Data  shown  as  mean  ±  SEM.  Significance  of
differences estimated with Tukey multiple com  -
parisons test 
Control ≠ all HUVECs cell counts, p < 0.0001 (**)
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F Fi ig gu ur re e    2 2. .    Comparison  of  the  ability  of  human
endothelial cells (HUVECs) vs. murine endothelial
cells (HECa10) to inhibit ADP-induced (5 ﾵM) platelet
aggregation monitored under in vitro conditions.
Data shown as mean ± SEM. Significance of dif  -
ferences estimated with the post hoc Tukey test for
multiple comparisons 
Control ≠ HUVECs, p < 0.0001 (**)
Control ≠ HECa10, p = 0.002 (*)
HUVECs ≠ HECa10, p = 0.025 (**)
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When comparing the inhibitory effectiveness of
EC originating from different species, we revealed
that  murine  endothelial  cell  line  HECa10  was
significantly less effective in hampering human
blood platelet aggregation. The mechanism(s) of
such difference(s) has not been extensively explored
in the present study. On the basis of our results and
literature data we cannot explain in depth the origin
of  observed  differences  between  murine  and
human  endothelial  cell  lines  [19].  We  have
formulated  a “general”  warning  addressed  to
researchers who extrapolate the outcomes of in
vitro studies on murine endothelium to studies of
human platelet-endothelium interactions.
Our observation deserves to be emphasized in
regard to potential exchangeability of the outcomes
of model studies using animal cell cultures, as
a cheaper substitute for cell cultures of human
origin.  Although  useful  in  some  physiological
studies, the outcomes of studies performed on such
models may not be unreservedly extrapolated to
discuss  any  further  perspectives  in  human
medicine. 
Thus,  our  present  findings  may  bear  some
disappointing implications for direct extrapolation(s)
of results collected using animal cell cultures to
target  particular  pharmacological  scenarios  in
humans. 
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